How Wilson, N.C., plays a critical role in our commitment to supply
Meet the North Carolina-based manufacturing team that’s producing and packaging our investigational oral antiviral COVID-19 medicine
March 2, 2022
From the earliest stages of the COVID-19 pandemic, we knew we had a responsibility to rise to the challenge of this unique moment. That’s why our teams mobilized like never before to ensure we were ready to address a global need.
In late 2020, our manufacturing teams began utilizing our global supply network — including sites in nine countries across three continents — to start production of our investigational oral antiviral COVID-19 medicine. This monumental effort made it possible for us to produce 10 million courses of therapy in 2021, with at least another 20 million on track for 2022.
A major part of that effort takes place in Wilson, North Carolina, where our colleagues are working tirelessly to carry out our mission and ensure supply during this crucial time.
“This is a perfect example of the company coming together as one team with a single goal,” said Francisco Toste, associate vice president, plant management at the Wilson site. “I am proud to work for our great company because of the impact that we make for patients around the world in helping them combat serious disease.”
Meet the team in Wilson behind this heroic effort: